Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer

LESSONS LEARNED. The negative results are consistent with the negative results of large phase III trials in which docetaxel plus antiangiogenic agents were used in patients with metastatic castrate‐resistant prostate cancer (mCRPC). The negative data underscore that, despite a sound biological ratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Heath, Elisabeth, Heilbrun, Lance, Mannuel, Heather, Liu, Glenn, Lara, Primo, Monk, J. Paul, Flaig, Thomas, Zurita, Amado, Mack, Philip, Vaishampayan, Ulka, Stella, Philip, Smith, Daryn, Bolton, Susan, Hussain, Arif, Al‐Janadi, Anas, Silbiger, Daniel, Usman, Muhammad, Ivy, S. Percy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738301/
https://www.ncbi.nlm.nih.gov/pubmed/31152080
http://dx.doi.org/10.1634/theoncologist.2019-0331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738301/
https://www.ncbi.nlm.nih.gov/pubmed/31152080
http://dx.doi.org/10.1634/theoncologist.2019-0331

Ejemplares similares